Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
Financials
Financial year 2025
RING PHARMA from Grimbergen, company number BE0472540052, closed financial year 2025 with a result of € -104,944 after tax. For that financial year RING PHARMA recorded a gross margin of € 22,429 and equity of € -2,412. Compared with financial year 2024, the result moved from € 5,037 to € -104,944. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.
€ -2,412
▼ € 104,944 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -104,944
▼ still € 5,037 profit in 2024
Profit after tax over the fiscal year.
€ 68,291
▼ 65% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -202,412.
People and assets in 2025
€ 38,026
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.6 million
▼ 23% vs 2024
Loans from banks and other lenders, long and short.
€ 475
▼ 87% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 62,887 | € 26,684 | € 37,930 | € 22,429 | ▼ 41% |
| Profit after taxes | € -53,935 | € -100,228 | € 5,037 | € -104,944 | ▼ € 109,981 |
| Equity | € 197,724 | € 97,495 | € 102,532 | € -2,412 | ▼ € 104,944 |
| Total debts | € 2,592,663 | € 2,319,779 | € 2,035,024 | € 1,573,410 | ▼ 23% |
| Cash | € 120,802 | € 84,368 | € 193,052 | € 68,291 | ▼ 65% |
| Land & buildings | € 547,529 | € 530,710 | € 513,890 | € 497,071 | ▼ 3% |
| Retained profit | € -2,276 | € -102,505 | € -97,468 | € -202,412 | ▼ € 104,944 |
| Bank debt | € 2,520,562 | € 2,312,592 | € 2,017,790 | € 1,554,217 | ▼ 23% |
| Balance sheet total | € 2,790,387 | € 2,417,275 | € 2,137,556 | € 1,570,999 | ▼ 27% |
Key figures of RING PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to RING PHARMA?
What happened at RING PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 104,944 (▼ € 109,981 vs 2024). Source: NBB ↗
- New establishment in Grimbergen. KBO
- Start of the company according to the CBE. KBO
In short
From € 53,935 loss in 2022 to € 104,944 loss in 2025.
Best year ever: 2024, with € 5,037 profit.
A new publication or filing at RING PHARMA? We notify you, reason included.
Follow RING PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind RING PHARMA is Marc Crepel. Marc Crepel is also behind INSIGO, 'T WIT PAARD, MAGISTRA BUILDING COMPANY, TOF Belgium Real Estate and ARO.
Directors
According to the 2025 annual accounts
Marc Crepel
Director
Also active at: INSIGO, 'T WIT PAARD, MAGISTRA BUILDING COMPANY, TOF Belgium Real Estate, ARO, IMMO GRYSPEIRT, BRASSERIE VISMET, WELLNESS BUILDING +1 more
Establishments
Establishment units
Physical locations of this company
Kerkeblokstraat 5-7
1850 Grimbergen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0472.540.052
- VAT number
- BE 0472.540.052
- Registered office
- Kerkeblokstraat 5-7, 1850 Grimbergen
- Names & denominations
- RING PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 August 2000
- Peppol
- Active · Active since 17 Nov 2025
- Activities · NACE
Markt- en opinieonderzoek
Marktonderzoekbureaus
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Handelsbemiddeling in meubels, huishoudelijke artikelen en ijzerwaren
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering